Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Long

Showing results (881-890 of 1,328) with videos related to

Pageof 133
Sort By:
Oncoimmunology|February 7, 2022
MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancerMasayuki Hagiwara, Atsushi Fushimi, Atrayee Bhattacharya, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside EnzalutamideJaimie S Gray, Sajad A Wani, Shahid Hussain, et al.
Blood|August 1, 1992
Dynamic assessment of quality of life after autologous bone marrow transplantationN J Chao, D K Tierney, J R Bloom, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2012
Diversification of complex butterfly wing patterns by repeated regulatory evolution of a Wnt ligandArnaud Martin, Riccardo Papa, Nicola J Nadeau, et al.
SVOA Neurology|February 7, 2022
Moderate Intensity Exercise in Pre-manifest Huntington's Disease: Results of a 6 months TrialAmro Saad Aldine, Amy Ogilvie, John Wemmie, et al.
BMC Gastroenterology|February 20, 2022
Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBDBenjamin Click, Edward L Barnes, Benjamin L Cohen, et al.
Inflammatory Bowel Diseases|March 4, 2025
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical ProgramBruce E Sands, Marla C Dubinsky, Paulo G Kotze, et al.
Bioorganic & Medicinal Chemistry Letters|January 16, 2013
A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucomaDaniel D Long, Bryan Frieman, Sharath S Hegde, et al.
Blood|September 1, 1994
Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phaseD S Snyder, R S Negrin, M R O'Donnell, et al.
Crohn'S & Colitis 360|February 13, 2023
Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug MonitoringAmy Hemperly, Marla C Dubinsky, Andres Yarur, et al.
Pageof 133

Showing results (881-890 of 1,328) with videos related to

Sort By:
Pageof 133
Oncoimmunology|February 7, 2022
MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancerMasayuki Hagiwara, Atsushi Fushimi, Atrayee Bhattacharya, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside EnzalutamideJaimie S Gray, Sajad A Wani, Shahid Hussain, et al.
Blood|August 1, 1992
Dynamic assessment of quality of life after autologous bone marrow transplantationN J Chao, D K Tierney, J R Bloom, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2012
Diversification of complex butterfly wing patterns by repeated regulatory evolution of a Wnt ligandArnaud Martin, Riccardo Papa, Nicola J Nadeau, et al.
SVOA Neurology|February 7, 2022
Moderate Intensity Exercise in Pre-manifest Huntington's Disease: Results of a 6 months TrialAmro Saad Aldine, Amy Ogilvie, John Wemmie, et al.
BMC Gastroenterology|February 20, 2022
Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBDBenjamin Click, Edward L Barnes, Benjamin L Cohen, et al.
Inflammatory Bowel Diseases|March 4, 2025
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical ProgramBruce E Sands, Marla C Dubinsky, Paulo G Kotze, et al.
Bioorganic & Medicinal Chemistry Letters|January 16, 2013
A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucomaDaniel D Long, Bryan Frieman, Sharath S Hegde, et al.
Blood|September 1, 1994
Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phaseD S Snyder, R S Negrin, M R O'Donnell, et al.
Crohn'S & Colitis 360|February 13, 2023
Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug MonitoringAmy Hemperly, Marla C Dubinsky, Andres Yarur, et al.
Pageof 133